# Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma

> **NCT00828594** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 130 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** RAD001
- **DRUG:** RAD001, sorafenib

## Key facts

- **NCT ID:** NCT00828594
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-12
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2013-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00828594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00828594, "Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00828594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*